

Composition

DLP 30 Capsule: Each capsule contains Dexlansoprazole INN 30 mg (as Enteric Coated Pellets)

DLP 60 Capsule: Each capsule contains Dexlansoprazole INN 60 mg (as Enteric Coated Pellets)

Description

DLP (Dexlansoprazole) delayed release capsule has been characterized as a gastric Proton Pump Inhibitor (PPI) that blocks the final step of gastric acid production. It is the R-enantiomer of Lansoprazole (a racemic mixture of the R and S-enantiomers). DLP (Dexlansoprazole) capsule contains enteric coated pellets with different pH - dependent dissolution profiles. The formulation of DLP (Dexlansoprazole) utilizes Dual Delayed Release (DDR) technology which results in plasma concentration-time profile with two distinct peaks; the first peak occurs within 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. No accumulation of Dexlansoprazole occurs after multiple once daily doses of DLP.

Indications

DLP (Dexlansoprazole) is a Proton Pump Inhibitor used to treat-

- 1. Healing of all grades of Erosive Esophagitis
- 2. Maintenance of healed Erosive Esophagitis
- 3. Heartburn associated with Non-Erosive Gastroesophageal reflux disease (GERD)

Dosage and Administration

Indications	Dose	Duration
Healing of Erosive Esophagitis	60 mg once daily	Up to 8 weeks
Maintenance of healed Erosive Esophagitis and relief of heartburn	30 mg once daily	Up to 6 months
Symptomatic Non-Erosive GERD	30 mg once daily	Up to 4 weeks

Contraindications

Dexlansoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation.

Side Effects

Diarrhea, abdominal pain, nausea, vomiting, flatulence etc.

Precautions

Patients taking concomitant Warfarin may require monitoring for increased International Normalized Ratio (INR) and Prothrombin time. Increased INR and Prothrombin time may lead to abnormal bleeding and even death.

Use In Pregnancy and Lactation

Dexlansoprazole is considered a US FDA pregnancy Category B drug. This means that Dexlansoprazole is probably safe for use during pregnancy, although the full risks are currently unknown.

Drug Interactions

Dexlansoprazole may interfere with the absorption of drugs for which gastric pH is important for bioavailability (e.g., Ampicillin esters, Digoxin, Iron salts, Ketoconazole).

Overdose

There have been no reports of significant overdose of Dexlansoprazole. Multiple doses of Dexlansoprazole 120 mg and a single dose of Dexlansoprazole 300 mg did not result in any severe adverse events.

Storage

Store below 30°C & dry place, away from light. Keep out of the reach of children.

Packing

DLP 30 Capsule: Each box contains 3 blister packs with each blister of 10

DLP 60 Capsule: Each box contains 3 blister packs with each blister of 10 capsules.

Manufactured by:

